ESMO Congress 2026

Dual CDK4/6 inhibitors have established clinical efficacy in HR+/HER2- advanced breast cancer and reshaped the treatment landscape ^[1][2], but neutropenia, a shared dose-limiting hematologic toxicity, has long constrained dose intensity and treatment continuity, and in turn antitumor efficacy ^[1][3]. The biological rationale: HR+ breast cancer cells are highly dependent on CDK4 but not CDK6, whereas human bone marrow-derived cells are insensitive to CDK4 loss because of the primary and compensatory role of CDK6 in hematopoiesis ^[1]. Atirmociclib (PF-07220060) was developed as a next-generation CDK4-selective inhibitor on exactly this logic; preclinical work showed its impact on circulating neutrophils was reduced in proportion with its increased CDK4-versus-CDK6 selectivity, and the realized dose intensification led to greater CDK4 inhibition and deeper antitumor responses ^[1]; its high selectivity combined efficacy in a mouse ZR75-1 xenograft model with minimal impact on neutrophils ^[2], with the expectation of ameliorating the dose-limiting hematologic toxicities of dual inhibitors ^[3].

At ESMO26's oral session (Proffered Paper Session 2, October 24, 08:30-10:00 CEST, Alicante Auditorium, Hall 6), Antonio Giordano presented the randomized phase 2 FOURLIGHT1 results: in patients with HR+/HER2- (ER+) advanced or metastatic breast cancer that progressed after prior endocrine therapy plus a CDK4/6 inhibitor, atirmociclib + fulvestrant was compared with TPC (fulvestrant or exemestane/everolimus). The key numbers: mPFS 9.4 vs 6.6 months, HR 0.60; the notable adverse event was neutropenia; and there was one treatment-related death in the atirmociclib arm, from pneumonitis.

This readout moves CDK4-selective inhibition from preclinical hypothesis to randomized phase 2 clinical evidence: in a post-CDK4/6-inhibitor population, atirmociclib plus fulvestrant still delivered a PFS improvement with HR 0.60, echoing the preclinical view that CDK4 target coverage is a limiting factor of dual-inhibitor efficacy ^[1]. There is also tension: the design rationale was to spare neutrophils through selectivity ^[1][2][3], yet neutropenia remained a notable AE in this trial. The live posts also flagged a second point: this 2L setting is no longer the development focus, Pfizer's focus has shifted to 1L, and a first-line trial and curative trials are coming.

As for limitations, the live posts did not disclose sample size, ORR, OS, or full safety data; the pneumonitis-related treatment death in the atirmociclib arm needs verification in the full report; and given that the 2L indication has been deprioritized by the company's strategy, the practical impact of this positive phase 2 readout depends more on whether the upcoming 1L program reads out successfully.